Short acting GLP-1 receptor agonist (injectable)
Lixisenatide 5 µg injection twice daily
LIXI_SC_5UG_BID
Related
- All doses pooled: Lixisenatide injection
- Lixisenatide 20 ug subcutaneous once daily
- Lixisenatide 5 µg injection once daily
- Lixisenatide 10 µg injection once daily
- Lixisenatide 30 µg injection once daily
- Lixisenatide 10 µg injection twice daily
- Lixisenatide 20 µg injection twice daily
- Lixisenatide 30 µg injection twice daily
- Lixisenatide 10 µg injection
- Lixisenatide 2.5 µg injection
- Lixisenatide 5 µg injection
- Lixisenatide 20 µg injection
Effects across outcomes
Bayesian random effects estimate against the comparator of each analysis (usually placebo), posterior median and 95% credible interval. Green: clearly better; red: clearly worse.
| Condition | Outcome | Window | Versus | Effect (95% CrI) | SUCRA |
|---|---|---|---|---|---|
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 0.81 (0.01 to 63.97) | 0.41 |
| Type 2 diabetes (adults) | Level 2 or 3 hypoglycemia (participants) | longest follow-up | Placebo | HR 4.54 (0.82 to 21.32) | 0.19 |
| Type 2 diabetes (adults) | Serious adverse events | longest follow-up | Placebo | HR 0.14 (0.00 to 1.88) | 0.85 |
| Type 2 diabetes (adults) | Nausea | longest follow-up | Placebo | HR 1.14 (0.32 to 3.16) | 0.74 |
| Type 2 diabetes (adults) | Vomiting | longest follow-up | Placebo | HR 3.25 (0.68 to 12.78) | 0.44 |
| Type 2 diabetes (adults) | Diarrhea | longest follow-up | Placebo | HR 0.63 (0.15 to 1.91) | 0.81 |
| Type 2 diabetes (adults) | Acute pancreatitis | longest follow-up | Placebo | HR 0.92 (0.06 to 15.46) | 0.46 |